Hasan Batuhan Arabaci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hasan Batuhan Arabaci has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Emre Uzun
Ankara Bilkent City Hospital
5 shared publications - Samet Senel
Ankara Bilkent City Hospital
5 shared publications - Antonios Koudonas
First Department of Urology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
4 shared publications - Cuneyt Ozden
Department of Urology, Ankara Bilkent City Hospital, Ankara, Turkey
3 shared publications - Kazim Ceviz
Department of Urology, Ankara Bilkent City Hospital, Ankara, Turkey
3 shared publications - Cavit Ceylan
University of Health Sciences Turkey, Ankara City Hospital, Clinic of Urology, Ankara, Turkey
2 shared publications
Latest Publications
- 7 November 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 1179
Effect of positive surgical margin characteristics on biochemical failure following robot-assisted radical prostatectomy
- 7 November 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 1179
Effect of positive surgical margin characteristics on biochemical failure following robot-assisted radical prostatectomy
- Open Access
- 23 June 2026
- Published by Springer Nature in BMC Urology
- Vol. 26 (1)
Variant histology in urothelial carcinoma: associated factors and survival impact after radical cystectomy
Purpose: To investigate the factors associated with variant histology (VH) and prognostic significance of VH in urothelial carcinoma (UC) among patients undergoing radical cystectomy (RC) with ileal conduit urinary diversion. Methods: A retrospective analysis was conducted on 317 patients who underwent RC with ileal conduit diversion between 2019 and 2025. Patients were categorized based on the presence of VH in the final pathology. Demographic, clinical, perioperative, and pathological data were compared. Logistic regression was performed to identify factors associated with VH, while Kaplan–Meier and uni-multivariable Cox regression analyses evaluated overall survival (OS) and cancer-specific survival (CSS). Results: VH was detected in 139 patients (43.8%), with squamous differentiation being the most prevalent variant, observed in 80 patients of the 317 patients who underwent RC with ileal conduit urinary diversion. Presence of hydronephrosis, clinical lymph node positivity and WBC > 7695 g/dl were defined as factors associated with VH in multivariate logistic regression analysis. Kaplan–Meier survival analysis illustrated a statistically significant reduction in OS and CSS among patients harboring VH compared to those with pure UC following RC and ileal conduit urinary diversion (53.8 vs. 36.8 months for OS and 68 vs. 53 months for CSS, log-rank test, p < 0.001). Multivariable Cox regression analysis revealed that presence of variant histology was associated with reduced OS (HR = 1.624; 95% CI = 1.094–2.411; p = 0.016) and CSS (HR = 1.945; 95% CI = 1.043–3.626; p = 0.036). Conclusion: VH in UC is associated with advanced disease and poorer survival outcomes following RC. Certain preoperative factors—hydronephrosis, clinical lymphadenopathy, and elevated WBC—may be associated with the presence of VH. Early recognition of these features could guide individualized treatment strategies and improve prognostic assessment. However, the retrospective and single-center nature of this study may introduce selection and information bias, and the findings should be interpreted with caution until validated by prospective multicenter trials.
- 23 June 2026
- Published by Springer Nature in BMC Urology
- Vol. 26 (1)
Open AccessVariant histology in urothelial carcinoma: associated factors and survival impact after radical cystectomy
Purpose: To investigate the factors associated with variant histology (VH) and prognostic significance of VH in urothelial carcinoma (UC) among patients undergoing radical cystectomy (RC) with ileal conduit urinary diversion. Methods: A retrospective analysis was conducted on 317 patients who underwent RC with ileal conduit diversion between 2019 and 2025. Patients were categorized based on the presence of VH in the final pathology. Demographic, clinical, perioperative, and pathological data were compared. Logistic regression was performed to identify factors associated with VH, while Kaplan–Meier and uni-multivariable Cox regression analyses evaluated overall survival (OS) and cancer-specific survival (CSS). Results: VH was detected in 139 patients (43.8%), with squamous differentiation being the most prevalent variant, observed in 80 patients of the 317 patients who underwent RC with ileal conduit urinary diversion. Presence of hydronephrosis, clinical lymph node positivity and WBC > 7695 g/dl were defined as factors associated with VH in multivariate logistic regression analysis. Kaplan–Meier survival analysis illustrated a statistically significant reduction in OS and CSS among patients harboring VH compared to those with pure UC following RC and ileal conduit urinary diversion (53.8 vs. 36.8 months for OS and 68 vs. 53 months for CSS, log-rank test, p < 0.001). Multivariable Cox regression analysis revealed that presence of variant histology was associated with reduced OS (HR = 1.624; 95% CI = 1.094–2.411; p = 0.016) and CSS (HR = 1.945; 95% CI = 1.043–3.626; p = 0.036). Conclusion: VH in UC is associated with advanced disease and poorer survival outcomes following RC. Certain preoperative factors—hydronephrosis, clinical lymphadenopathy, and elevated WBC—may be associated with the presence of VH. Early recognition of these features could guide individualized treatment strategies and improve prognostic assessment. However, the retrospective and single-center nature of this study may introduce selection and information bias, and the findings should be interpreted with caution until validated by prospective multicenter trials.
- Open Access
- 28 February 2026
- Published by Pera Yayıncılık Hizmetleri in The New Journal of Urology
- Vol. 21 (1) , 39
Effects of Neoadjuvant Chemotherapy Treatment on Perioperative Outcomes Following Radical Cystectomy
Objective: This study aimed to assess the impact of neoadjuvant chemotherapy (NAC) on perioperative outcomes in patients undergoing radical cystectomy (RC) for urothelial carcinoma. Materials and Methods: We retrospectively analyzed the clinical records of 317 patients who underwent RC and ileal loop diversion between February 2019 and May 2025. Patients were categorized into NAC+RC and RC-only groups. Demographic, preoperative, intraoperative, and postoperative variables were evaluated. Propensity score matching (PSM) was conducted to match the groups in a 1:1 ratio using the nearest-neighbor matching algorithm in terms of age, body mass index (BMI), previous surgery history, American Society of Anesthesiologists (ASA) score, preoperative T stage, hemoglobin, white blood cell (WBC), incision length and urinary diversion technique. Results: Among the 317 patients, 60 (18.9%) received NAC+RC and 257 (81.1%) underwent RC alone. Preoperative T2 stage was more prevalent in the NAC group compared with the RConly group (85% vs. 68.5%, p=0.024). Preoperative hemoglobin (12.6 vs. 11.9 g/dL, p=0.006) and white blood cell levels (8886.9 vs. 7416.8/μL, p<0.001) were significantly higher in the RConly group. Postoperative complications were more frequent among RC-only patients (47.5% vs. 31.7%, p=0.027). After PSM, 57 matched pairs were obtained. The RC-only group demonstrated higher blood transfusion requirements (1 vs. 0 units, p = 0.048), longer hospitalization (17 vs. 15 days, p=0.015), and delayed return to oral intake (3 vs. 3 days, p=0.028) compared with the matched NAC+RC group. Although complications were more common in the RC-only group, the difference was not statistically significant (29% vs. 19%, p=0.058). Conclusion: NAC does not adversely affect perioperative morbidity following RC and may enhance specific postoperative recovery parameters. These findings support the safety and clinical value of NAC in appropriately selected patients with muscle-invasive bladder cancer. Keywords: complication, neoadjuvant chemotherapy, radical cystectomy, treatment
- 28 February 2026
- Published by Pera Yayıncılık Hizmetleri in The New Journal of Urology
- Vol. 21 (1) , 39
Open AccessEffects of Neoadjuvant Chemotherapy Treatment on Perioperative Outcomes Following Radical Cystectomy
Objective: This study aimed to assess the impact of neoadjuvant chemotherapy (NAC) on perioperative outcomes in patients undergoing radical cystectomy (RC) for urothelial carcinoma. Materials and Methods: We retrospectively analyzed the clinical records of 317 patients who underwent RC and ileal loop diversion between February 2019 and May 2025. Patients were categorized into NAC+RC and RC-only groups. Demographic, preoperative, intraoperative, and postoperative variables were evaluated. Propensity score matching (PSM) was conducted to match the groups in a 1:1 ratio using the nearest-neighbor matching algorithm in terms of age, body mass index (BMI), previous surgery history, American Society of Anesthesiologists (ASA) score, preoperative T stage, hemoglobin, white blood cell (WBC), incision length and urinary diversion technique. Results: Among the 317 patients, 60 (18.9%) received NAC+RC and 257 (81.1%) underwent RC alone. Preoperative T2 stage was more prevalent in the NAC group compared with the RConly group (85% vs. 68.5%, p=0.024). Preoperative hemoglobin (12.6 vs. 11.9 g/dL, p=0.006) and white blood cell levels (8886.9 vs. 7416.8/μL, p<0.001) were significantly higher in the RConly group. Postoperative complications were more frequent among RC-only patients (47.5% vs. 31.7%, p=0.027). After PSM, 57 matched pairs were obtained. The RC-only group demonstrated higher blood transfusion requirements (1 vs. 0 units, p = 0.048), longer hospitalization (17 vs. 15 days, p=0.015), and delayed return to oral intake (3 vs. 3 days, p=0.028) compared with the matched NAC+RC group. Although complications were more common in the RC-only group, the difference was not statistically significant (29% vs. 19%, p=0.058). Conclusion: NAC does not adversely affect perioperative morbidity following RC and may enhance specific postoperative recovery parameters. These findings support the safety and clinical value of NAC in appropriately selected patients with muscle-invasive bladder cancer. Keywords: complication, neoadjuvant chemotherapy, radical cystectomy, treatment
- Open Access
- 29 June 2025
- Published by Pera Yayıncılık Hizmetleri in The New Journal of Urology
- Vol. 20 (2) , 97
Intravesical Prostatic Protrusion and Surgical Outcomes in Benign Prostatic Hyperplasia: A Magnetic Resonance Imaging-Based Evaluation
Objective: This study aimed to investigate the impact of preoperative intravesical prostatic protrusion (IPP) measurements obtained via magnetic resonance imaging (MRI) on postoperative outcomes in patients undergoing transurethral resection of the prostate (TURP) for benign prostatic hyperplasia (BPH). Material and Methods: A retrospective review was performed on 160 patients who underwent monopolar TURP at our clinic between January 2021 and December 2023. IPP was measured on sagittal MRI images as the vertical distance from the bladder base to the tip of the prostate protruding into the bladder. Patients were divided into three groups according to IPP length: Group A (IPP <5 mm, n=25), Group B (5 mm ≤ IPP <10 mm, n=30), and Group C (IPP ≥10 mm, n=38). Preoperative and postoperative data, including prostate-specific antigen (PSA) levels, International Prostate Symptom Score (IPSS), average urinary flow rate (Qavg), and maximum urinary flow rate (Qmax), were collected and analyzed across the groups. Results: The mean age of the patients was 65.3 ± 6.7 years. PSA levels were significantly higher in Group C compared to Group A (p=0.014). Prostate volume and the volume of resected tissue were significantly greater in Group C than in Groups A and B (p<0.001). Postoperatively, all groups showed significant decreases in PSA and IPSS values, along with significant increases in Qmax and Qavg. The improvement in Qmax after TURP was significantly greater in Groups B and C compared to Group A (p=0.019). However, the reduction in IPSS scores did not differ significantly among the groups (p=0.727). Conclusion: IPP correlates positively with prostate volume, PSA levels, and the amount of resected tissue. TURP significantly improves urinary function and symptom scores regardless of IPP length. However, the improvement in Qmax is more pronounced in patients with a higher IPP. IPP measurement may serve as a useful parameter in the surgical decision-making process for BPH patients. Keywords: intravesical prostatic protrusion, benign prostatic hyperplasia, transurethral resection of the prostate, magnetic resonance imaging, urinary function.
- 29 June 2025
- Published by Pera Yayıncılık Hizmetleri in The New Journal of Urology
- Vol. 20 (2) , 97
Open AccessIntravesical Prostatic Protrusion and Surgical Outcomes in Benign Prostatic Hyperplasia: A Magnetic Resonance Imaging-Based Evaluation
Objective: This study aimed to investigate the impact of preoperative intravesical prostatic protrusion (IPP) measurements obtained via magnetic resonance imaging (MRI) on postoperative outcomes in patients undergoing transurethral resection of the prostate (TURP) for benign prostatic hyperplasia (BPH). Material and Methods: A retrospective review was performed on 160 patients who underwent monopolar TURP at our clinic between January 2021 and December 2023. IPP was measured on sagittal MRI images as the vertical distance from the bladder base to the tip of the prostate protruding into the bladder. Patients were divided into three groups according to IPP length: Group A (IPP <5 mm, n=25), Group B (5 mm ≤ IPP <10 mm, n=30), and Group C (IPP ≥10 mm, n=38). Preoperative and postoperative data, including prostate-specific antigen (PSA) levels, International Prostate Symptom Score (IPSS), average urinary flow rate (Qavg), and maximum urinary flow rate (Qmax), were collected and analyzed across the groups. Results: The mean age of the patients was 65.3 ± 6.7 years. PSA levels were significantly higher in Group C compared to Group A (p=0.014). Prostate volume and the volume of resected tissue were significantly greater in Group C than in Groups A and B (p<0.001). Postoperatively, all groups showed significant decreases in PSA and IPSS values, along with significant increases in Qmax and Qavg. The improvement in Qmax after TURP was significantly greater in Groups B and C compared to Group A (p=0.019). However, the reduction in IPSS scores did not differ significantly among the groups (p=0.727). Conclusion: IPP correlates positively with prostate volume, PSA levels, and the amount of resected tissue. TURP significantly improves urinary function and symptom scores regardless of IPP length. However, the improvement in Qmax is more pronounced in patients with a higher IPP. IPP measurement may serve as a useful parameter in the surgical decision-making process for BPH patients. Keywords: intravesical prostatic protrusion, benign prostatic hyperplasia, transurethral resection of the prostate, magnetic resonance imaging, urinary function.
- 28 July 2024
- Published by Springer Nature in Urolithiasis
- Vol. 52 (1) , 1-8
The predictive ability of Mayo adhesive probability score for evaluating intraoperative bleeding in standard percutaneous nephrolithotomy in adult patients
Mayo adhesive probability (MAP) score is one of the commonest tool to predict the adherence status of perirenal fat. The association between MAP score and intraoperative hemorrhage in patients undergoing micropercutaneous nephrolithotomy was comfirmed in a recent well designed study. We aimed to investigate if MAP score may predict the possibility for significant intraoperative bleeding in supine percutaneous nephrolithotomy (PCNL) performed with a 26 Fr rigid nephroscope. In this observational retrospective study, demographic, clinical, laboratory, radiological, perioperative (operation duration, hospitalization, intraoperative bleeding, success) and MAP score (perinephric fat stranding, posterior perinephric fat thickness and total MAP score) data of all patients who underwent supine PCNL between June 2021 and July 2023 were evaluated. The patients were divided into 2 groups according to their MAP scores (79 [54.1%] patients with MAP score < 3 [low MAP score] and 67 [54.1%] patients with MAP score ≥ 3 [high MAP score]). The rate of patients with intraoperative bleeding was 47.8% in the patient group with a high MAP score, while it was 22.8% in the patient group with a low MAP score (p = 0.002). In multivariate logistic regression analysis, anticoagulant drug use history (OR = 2.525; 95% CI = 1.025–6.224; p = 0.044), presence of multiple stones (OR = 3.015; 95% CI = 1.205–7.543; p = 0.018), calyx localization of the stone (OR = 2.871;95% CI = 1.166–7.068; p = 0.022), higher renal parenchymal thickness (OR = 1.119; 95% CI = 1.049–1.193; p = 0.001) and MAP score > 3 (OR = 3.486; 95% CI = 1.579–7.696; p = 0.002) were defined as independent risk factors for significant intraoperative bleeding. In clinical practice, the MAP score can be used to predict bleeding before PCNL.
- 28 July 2024
- Published by Springer Nature in Urolithiasis
- Vol. 52 (1) , 1-8
The predictive ability of Mayo adhesive probability score for evaluating intraoperative bleeding in standard percutaneous nephrolithotomy in adult patients
Mayo adhesive probability (MAP) score is one of the commonest tool to predict the adherence status of perirenal fat. The association between MAP score and intraoperative hemorrhage in patients undergoing micropercutaneous nephrolithotomy was comfirmed in a recent well designed study. We aimed to investigate if MAP score may predict the possibility for significant intraoperative bleeding in supine percutaneous nephrolithotomy (PCNL) performed with a 26 Fr rigid nephroscope. In this observational retrospective study, demographic, clinical, laboratory, radiological, perioperative (operation duration, hospitalization, intraoperative bleeding, success) and MAP score (perinephric fat stranding, posterior perinephric fat thickness and total MAP score) data of all patients who underwent supine PCNL between June 2021 and July 2023 were evaluated. The patients were divided into 2 groups according to their MAP scores (79 [54.1%] patients with MAP score < 3 [low MAP score] and 67 [54.1%] patients with MAP score ≥ 3 [high MAP score]). The rate of patients with intraoperative bleeding was 47.8% in the patient group with a high MAP score, while it was 22.8% in the patient group with a low MAP score (p = 0.002). In multivariate logistic regression analysis, anticoagulant drug use history (OR = 2.525; 95% CI = 1.025–6.224; p = 0.044), presence of multiple stones (OR = 3.015; 95% CI = 1.205–7.543; p = 0.018), calyx localization of the stone (OR = 2.871;95% CI = 1.166–7.068; p = 0.022), higher renal parenchymal thickness (OR = 1.119; 95% CI = 1.049–1.193; p = 0.001) and MAP score > 3 (OR = 3.486; 95% CI = 1.579–7.696; p = 0.002) were defined as independent risk factors for significant intraoperative bleeding. In clinical practice, the MAP score can be used to predict bleeding before PCNL.
- 28 November 2023
- Published by Springer Nature in Urolithiasis
- Vol. 52 (1) , 1-7
Development of a new scoring system predicting medical expulsive therapy success on 4–10 mm distal ureteral stones: medical expulsive therapy stone score (METSS)
Ureteral stone passage by using medical expulsive therapy (MET) are affected by numerous radiological and clinical parameters. We aimed to construct a scoring system, which would be based on clinical and computed tomography (CT)-derived data, to predict the success of the MET approach. 186 patients presenting to urology clinic or emergency department with unilateral single 4–10 mm distal ureteral stone and who had MET were included. All patients were divided into two groups as the MET-successful group and the MET-unsuccessful group. The success rate of MET was 67.2%. Stone size ≥ 6.5 mm, stone density > 1078 HU, ureteral wall thickness (UWT) > 2.31 mm, ureteral diameter (UD) > 9.24 mm, presence of periureteral stranding (PUS) and presence of diabetes mellitus (DM) were stated as the independent risk factors. Based on the regression coefficients on multivariate logistic regression analysis, 1 point for stone size > 6.5 mm, 2 points for stone density > 1078 HU, 2 points for UWT > 2.31 mm, 3 points for UD > 9.24 mm, 1 point for presence of PUS and 1 point for presence of DM were assigned to patients for each risk factor. Higher medical expulsive therapy stone score (METSS) indicated lower MET success. All patients were classified into three risk groups according to METSS: low risk (0–3 points; success percentage: 92.8%); intermediate risk (4–5 points; success percentage: 60.4%) and high risk (6–10 points; success percentage: 8.3%). The METSS seems to separate successfully the patients with a favorable or adverse constellation of factors.
- 28 November 2023
- Published by Springer Nature in Urolithiasis
- Vol. 52 (1) , 1-7
Development of a new scoring system predicting medical expulsive therapy success on 4–10 mm distal ureteral stones: medical expulsive therapy stone score (METSS)
Ureteral stone passage by using medical expulsive therapy (MET) are affected by numerous radiological and clinical parameters. We aimed to construct a scoring system, which would be based on clinical and computed tomography (CT)-derived data, to predict the success of the MET approach. 186 patients presenting to urology clinic or emergency department with unilateral single 4–10 mm distal ureteral stone and who had MET were included. All patients were divided into two groups as the MET-successful group and the MET-unsuccessful group. The success rate of MET was 67.2%. Stone size ≥ 6.5 mm, stone density > 1078 HU, ureteral wall thickness (UWT) > 2.31 mm, ureteral diameter (UD) > 9.24 mm, presence of periureteral stranding (PUS) and presence of diabetes mellitus (DM) were stated as the independent risk factors. Based on the regression coefficients on multivariate logistic regression analysis, 1 point for stone size > 6.5 mm, 2 points for stone density > 1078 HU, 2 points for UWT > 2.31 mm, 3 points for UD > 9.24 mm, 1 point for presence of PUS and 1 point for presence of DM were assigned to patients for each risk factor. Higher medical expulsive therapy stone score (METSS) indicated lower MET success. All patients were classified into three risk groups according to METSS: low risk (0–3 points; success percentage: 92.8%); intermediate risk (4–5 points; success percentage: 60.4%) and high risk (6–10 points; success percentage: 8.3%). The METSS seems to separate successfully the patients with a favorable or adverse constellation of factors.